Skip to main
BIO

Bio-Rad Laboratories (BIO) Stock Forecast & Price Target

Bio-Rad Laboratories (BIO) Analyst Ratings

Based on 3 analyst ratings
Hold
Strong Buy 0%
Buy 33%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Bio-Rad Laboratories is poised to see strong sales growth as it laps headwinds from process chromatography in 2027 and implements a meaningful restructuring program that aims to improve margins. The company's ownership stake in Sartorius, which is set to increase in value once the controlling Trust terminates in mid-2028, adds potential upside to its stock. While Bio-Rad's sustainability integration is limited, its core business aligned with positive health outcomes, and the company has announced sustainability goals.

Bears say

Bio-Rad Laboratories is a diversified company with a majority of its revenue coming from the clinical diagnostics market and the rest from the life sciences market. However, multiple factors such as a potential loss of confidence in the company's sales and margin trajectory and a potential decrease in the value of its stake in Sartorius could lead to further multiple erosion and a lower stock price. This potential downside scenario is exacerbated by risks such as a longer-than-expected recovery in end markets, continued share losses in ddPCR, and uncertainties surrounding the company's M&A strategy and the potential impact of AI on the life sciences industry. Additionally, the company's corporate governance structure, with a single family controlling a majority of the voting power, could create further uncertainty in the company's direction and may not align with other shareholders.

Bio-Rad Laboratories (BIO) has been analyzed by 3 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 33% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bio-Rad Laboratories and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bio-Rad Laboratories (BIO) Forecast

Analysts have given Bio-Rad Laboratories (BIO) a Hold based on their latest research and market trends.

According to 3 analysts, Bio-Rad Laboratories (BIO) has a Hold consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $350, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $350, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bio-Rad Laboratories (BIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.